MDACC Study No:2012-0759 ( NCT No: NCT01610206)
Title:A randomized open label phase II study of weekly gemcitabine plus pazopanib versus weekly gemcitabine alone in the treatment of patients with persistent or relapsed epithelial ovarian, fallopian tube or primary peritoneal carcinoma
Principal Investigator:Jubilee Brown
Treatment Agent:Gemcitabine; Pazopanib
Study Status:Closed
Study Description:The goal of this clinical research study is to compare the effectiveness of the
combination of gemcitabine and pazopanib to gemcitabine alone in patients with
ovarian cancer, Fallopian tube cancer, or primary peritoneal cancer.
Researchers also want to learn about the possible side effects and safety of
the study drug combination.

Gemcitabine is designed to block the growth of cancer cells, which may cause
them to die.

Pazopanib is designed to block the growth of blood vessels that supply
nutrients needed for tumor growth. This may prevent or slow the growth of
cancer cells.
Hide details for General InformationGeneral Information

Disease Group:Fallopian Tube; Ovary; Peritoneum
Phase of Study:Phase II
Treatment Agents:Gemcitabine
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:GlaxoSmithKline
University of Virginia School of Medicine
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jubilee Brown
Dept:Gynecologic Oncology
For Clinical Trial Enrollment:713-792-1380
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults